Drug Profile
Research programme: anticancer monoclonal antibody therapies - Chinese Academy of Medical Sciences/Sanofi-aventis
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Chinese Academy of Medical Sciences; sanofi-aventis
- Developer Chinese Academy of Medical Sciences; Sanofi
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 14 Sep 2007 Preclinical trials in Cancer in China (Parenteral)